Defective Medical Device Claims

Medical devices — hip implants, surgical mesh, pacemakers, insulin pumps, diagnostic equipment — are held to high expectations because they are implanted in or used directly on the body. When devices fail, the injuries are often severe: revision surgeries, organ damage, infections, and permanent impairment. Claims for defective devices form a major category of product liability practice.

Device defects mirror the product-liability taxonomy. Design defects allege the device was unsafe as designed — metal-on-metal hip implants shedding debris, mesh products eroding into tissue. Manufacturing defects allege particular units were flawed. Failure-to-warn claims allege inadequate disclosure of risks to physicians or patients.

The FDA's device approval pathways shape litigation significantly. Devices approved through the rigorous premarket approval (PMA) process receive stronger federal preemption protection against state tort claims than devices cleared through the less demanding 510(k) process (which requires only substantial equivalence to an existing device). This regulatory distinction has profound litigation consequences.

Physicians and Hospitals as Parties

Beyond manufacturers, device claims sometimes implicate the physicians who selected or implanted the device and the hospitals where implantation occurred. Informed consent regarding device risks, proper implantation technique, and post-implant monitoring are the physician-side issues. But the core of most device litigation is the manufacturer's conduct: design choices, testing, warnings, and post-market surveillance.

Sales representative involvement in surgeries — device reps present in operating rooms advising on their products — raises questions about the manufacturer's role in individual procedures and the adequacy of physician training.

Mass Tort Patterns

Defective device cases, like defective drug cases, frequently proceed as mass torts: thousands of plaintiffs with the same implant experiencing similar failures. The litigation develops common evidence about the device's defects while preserving individual causation and damages inquiries.

Damages include revision surgeries, permanent injuries from device failures, and the cascading consequences of each. Device litigation illustrates the stakes of the FDA's gatekeeping role and the tort system's backstop function when regulation proves insufficient.

The 510(k) Clearance Pathway

The 510(k) pathway clears medical devices based on substantial equivalence to existing predicate devices, without requiring independent proof of safety and effectiveness. The pathway was designed for moderate-risk devices, but its use expanded to include implantable devices whose failures generate the most serious litigation. The clearance standard — equivalence, not safety — is frequently misunderstood as FDA approval of the device's safety.

Predicate creep compounds the concern: each new device need only be equivalent to its predicate, which was equivalent to its own predicate, creating chains stretching back to devices cleared under minimal scrutiny decades ago. A device on the market today may trace its lineage to predicates that would never survive current review — yet each link in the chain was legally sufficient.

Courts have generally held that 510(k) clearance does not preempt state tort claims, precisely because the pathway imposes no safety requirements that state law would duplicate. This doctrinal result channels the most serious device litigation — hips, mesh, morcellators — into state courts, where juries evaluate the devices' safety without deference to the clearance.

The regulatory debate continues: reform proposals would strengthen the pathway's requirements or restrict its use for implantables, while industry warns of innovation costs. Whatever the regulatory future, the litigation present treats 510(k) clearance as what it is — a regulatory classification decision, not a safety determination — and evaluates device safety on the evidence.

Surgical Mesh Litigation in General Terms

Surgical mesh products — used in hernia repair and pelvic organ procedures — generated large-scale litigation over complications including erosion into surrounding tissue, chronic pain, infection, and organ perforation. The claims alleged design defects (mesh materials and designs prone to complications), inadequate testing, and failure to warn physicians and patients of the risks' frequency and severity.

The litigation's scale — tens of thousands of plaintiffs — made it among the largest medical device mass torts, proceeding through multidistrict litigation with bellwether trials establishing valuation ranges. The proceedings developed extensive common evidence about the products' design history, the manufacturers' knowledge, and the complication rates.

Regulatory responses evolved alongside the litigation: FDA reclassifications imposing stricter requirements, safety communications about the risks, and orders to stop selling certain products. The interplay between the regulatory actions and the tort claims illustrates the two systems' complementary roles — regulation addressing future sales, litigation addressing past harms.

Related reading: Birth Injuries and Medical Malpractice: The Basics

This article provides general information only and is not legal advice.

Find a qualified attorney at Justice Lookup.

This article is general information, not legal advice. It does not create an attorney-client relationship.